SBC Medical Group (NASDAQ:SBC) Rating Increased to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded SBC Medical Group to “strong-buy” from “buy,” although analyst sentiment remains mixed overall: MarketBeat reports an average “hold” rating and an $8.50 consensus price target.
• SBC shares opened at $4.75, up 1.3%, with a market capitalization of about $488.5 million. The stock trades near its 12-month high of $4.97 and has risen above its 50-day and 200-day moving averages.
• The company exceeded quarterly revenue expectations with $49.19 million but missed earnings estimates, reporting $0.10 per share versus $0.12 expected. Institutional investors own 60.82% of the stock, with BlackRock among the firms establishing a new position.

SBC Medical Group (NASDAQ:SBC - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Saturday, Wall Street Zen reports.

SBC has been the subject of a number of other reports. Weiss Ratings restated a "sell (d+)" rating on shares of SBC Medical Group in a research report on Wednesday, August 19th. BTIG Research reiterated a "buy" rating and issued a $8.00 target price on shares of SBC Medical Group in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, SBC Medical Group presently has an average rating of "Hold" and a consensus price target of $8.50.

SBC Medical Group Stock Up 1.3%

Shares of SBC opened at $4.75 on Friday. The firm has a market cap of $488.54 million, a P/E ratio of 10.11 and a beta of 0.63. SBC Medical Group has a 12 month low of $2.78 and a 12 month high of $4.97. The stock's 50 day moving average is $3.66 and its two-hundred day moving average is $3.53. The company has a current ratio of 3.31, a quick ratio of 3.27 and a debt-to-equity ratio of 0.09.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%.The business had revenue of $49.19 million for the quarter, compared to analyst estimates of $45.37 million. Analysts predict that SBC Medical Group will post 0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SBC Medical Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in SBC. BlackRock Inc. acquired a new stake in shares of SBC Medical Group in the second quarter valued at about $2,846,000. Citadel Advisors LLC acquired a new position in SBC Medical Group during the second quarter worth about $446,000. Segall Bryant & Hamill LLC purchased a new stake in SBC Medical Group during the 1st quarter valued at about $340,000. Bank of New York Mellon Corp purchased a new stake in SBC Medical Group during the 2nd quarter valued at about $83,000. Finally, Central Pacific Bank Trust Division purchased a new stake in SBC Medical Group during the 2nd quarter valued at about $74,000. Institutional investors and hedge funds own 60.82% of the company's stock.

About SBC Medical Group

SBC Medical Group NASDAQ: SBC is a Japan-based medical services and management company focused primarily on the aesthetic medicine sector. Through its affiliated medical corporations and clinic network, the company supports the operation of facilities offering cosmetic surgery, cosmetic dermatology and related elective treatments.

The company provides a range of management and operational services to affiliated clinics, including branding and marketing, staff recruitment and training, purchasing, information technology, administrative support and business consulting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.